Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study
Year: 2024
Type: conference-abstract
Source: Blood
Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Cleveland Clinic, Tulane University, Memorial Healthcare System, Medical College of Wisconsin, The University of Texas MD Anderson Cancer Center, UMass Memorial Medical Center, Roche (United Kingdom), F. Hoffmann-La Roche AG, University of California, Irvine
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405045346
